Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTP4A3 | O75365 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 2/20 | 0.37 |
| ▸ | LPO | P22079 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1756847 | 0.81 | TBXAS1 (0.40) | PTP4A3FDPSLPOCYP2D6L3MBTL1 | |
| SCHEMBL7171507 | 0.81 | PTP4A3 (0.38) | PTP4A3FDPSLPOSMN1; SMN2KDM4E | |
| SCHEMBL7171508 | 0.81 | PTP4A3 (0.38) | PTP4A3FDPSLPOSMN1; SMN2KDM4E | |
| SCHEMBL1756842 | 0.81 | TBXAS1 (0.40) | PTP4A3FDPSLPOCYP2D6L3MBTL1 | |
| SCHEMBL16532700 | 0.80 | ALDH1A1 (0.40) | PTP4A3FDPSSMN1; SMN2SMYD3ALDH1A1 | |
| SCHEMBL19890620 | 0.79 | PTP4A3 (0.37) | PTP4A3FDPSLPOSMN1; SMN2ALDH1A1 | |
| SCHEMBL16532719 | 0.79 | PTP4A3 (0.37) | PTP4A3FDPSLPOSMN1; SMN2KDM4E | |
| SCHEMBL24149775 | 0.77 | PTP4A3 (0.35) | PTP4A3FDPSLPOCHRNB2CHRNA4 | |
| SCHEMBL16854062 | 0.77 | CCNC (0.40) | PTP4A3FDPSLPOSMN1; SMN2CYP2D6 | |
| SCHEMBL16850496 | 0.77 | KMT2A (0.36) | PTP4A3FDPSLPOSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018002-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC | 2023-02-09 | — | — | US | disclosed |
| US-11208388-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200172495-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2020-06-04 | — | — | US | disclosed |
| US-10544106-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20180072688-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180072688-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | PTP4A3 2093/4885FDPS 887/4885LPO 4394/4885 |
| US-10544106-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | PTP4A3 2093/4885FDPS 887/4885LPO 4394/4885 |
| US-12018002-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | PTP4A3 2093/4885FDPS 887/4885LPO 4394/4885 |
| US-11208388-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | PTP4A3 2093/4885FDPS 887/4885LPO 4394/4885 |
| US-20180072688-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | PTP4A3 2093/4885FDPS 887/4885LPO 4394/4885 |
| US-20200172495-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | PTP4A3 2093/4885FDPS 887/4885LPO 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.